603 completed, 70 terminated, 57 unknown, 31 withdrawn. 271 Phase 2, 225 Phase 3, 151 Phase 4, 51 Phase 1, 35 Not applicable.
Follow Ribavirin: new trials by email Literature Review of Ribavirin trials Research Report on Ribavirin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treatment of CKD Patients With HCV SOF+DCV, OBV/PTV/r) ± ribavirin (RBV) - HCV Infection ( Genotype 4) in CKD Patients | Phase 2 / Phase 3 | Not yet recruiting | Tanta University | 50 | 2026-09-15 | 2026-08-20 |
| ISTH/ANRS 0409s INTEGRATE Lassa Fever Study Favipiravir, Ribavirin, Dexamethasone - Lassa Fever | Phase 2 / Phase 3 | Recruiting | Irrua Specialist Teaching Hospital | 1755 | 2025-05-02 | 2026-02-04 |
| The Comparative Efficacy of Standard Treatment Plus Ribavirin vs Standard Treatment Alone in Preventing Clinically Significant Hemorrhage in Patients With Dengue Fever Ribavirin, Standard Treatment - Dengue Fever, Dengue Hemorrhagic Fever | Phase 3 | Completed | Khyber Medical University Peshawar | 284 | 2024-12-17 | 2025-06-26 |
| Assessing Antiviral Treatments in Early Symptomatic RSV Ribavirin, Molnupiravir, Favipiravir - Respiratory Syncytial Virus, Respiratory Syncytial Virus, Human | Phase 2 | Recruiting | University of Oxford | 1000 | 2024-07-25 | 2025-07-02 |
| LAssa Fever Adjunct Treatment With DEXamethasone Dexamethasone, Ribavirin - Lassa Fever | Phase 2 | Recruiting | Bernhard Nocht Institute for Tropical Medicine | 42 | 2024-02-05 | 2025-02-06 |
| Efficacy of 12 Weeks Versus 24 Weeks Treatment of Directly Acting Antiviral Therapy in Patients With Hepatitis C Related Chronic Liver Disease 12 weeks Sofosbuvir 400 mg once daily, Daclatasvir 60 mg once daily, and Ribavirin 400 mg twice daily - Heptatitis C | Not applicable | Completed | Indus Hospital and Health Network | 192 | 2024-01-10 | 2026-07-14 |
| UMIT-1 Trial Favipiravir & Ribavirin for the Treatment of CCHF Favipiravir, Ribavirin - CCHF | Phase 1 / Phase 2 | Unknown | Liverpool School of Tropical Medicine | 24 | 2023-07-12 | 2023-10-05 |
| Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy Bevacizumab, Atezolizumab, Sofosbuvir - Liver Cancer | Phase 4 | Terminated | M.D. Anderson Cancer Center | 2 | 2023-03-17 | 2024-12-31 |
| Treatment of Hemorrhagic Fever With Ribavirin Virazole - Hemorrhagic Fever | Phase 2 | Suspended | U.S. Army Medical Research and Development Command | 50 | 2022-10-31 | 2026-07-07 |
| Efficacy and Safety of SOF/VEL + RBV and SOF/VEL/VOX for 12 Weeks in HCV Subjects With GT3b and Compensated Cirrhosis Sofosbuvir/Velpatasvir + Ribavirin, Sofosbuvir/Velpatasvir/Voxilaprevir - Hepatitis C, Cirrhosis | Phase 4 | Unknown | Peking University People's Hospital | 100 | 2022-09-01 | 2022-07-21 |
| Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19_#2 50 mg/mL Virazole, 100 mg/mL Virazole - COVID19 | Phase 1 | Withdrawn | Bausch Health Americas, Inc. | 2021-05-01 | 2025-09-16 | |
| Efficacy and Safety of Favipiravir and Ribavirin Formulation for Treatment of COVID-19 Ribavirin Capsules, Favipiravir - SARS-CoV2, COVID-19 | Phase 2 / Phase 3 | Unknown | The Scientific and Technological Research Council of Turkey | 100 | 2021-04-01 | 2021-04-02 |
| Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19 50 mg/mL Virazole, 100 mg/mL Virazole - COVID19 | Phase 1 | Completed | Bausch Health Americas, Inc. | 51 | 2021-02-10 | 2021-08-26 |
| A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19 Nitazoxanide, Placebo Nitazoxanide, Ribavirin - SARS-CoV Infection, Covid19 | Phase 2 | Terminated | Rutgers, The State University of New Jersey | 7 | 2020-12-02 | 2022-05-05 |
| The Pharmacokinetics of P1101 + Ribavirin in Interferon Treatment-Naïve Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection P1101 + Ribavirin - Hepatitis C, Chronic | Phase 1 | Completed | PharmaEssentia | 17 | 2020-11-26 | 2022-08-30 |
| Combined Ribavirin With Sofosbuvir/Velpatasvir/Voxilaprevir in Retreatment of Chronic Hepatitis C Non-responders Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi] plus Ribavirin, Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi] - Chronic Hepatitis C | Phase 4 | Completed | Helwan University | 281 | 2020-11-21 | 2022-09-02 |
| Bioequivalence Study of Ribavirin in Healthy Adult Subjects Under Fed Condition Ribavirin 400 mg film coated tablet (1*400mg), Copegus® 200 mg film coated tablet (2*200mg) - Healthy Subjects | Phase 1 | Completed | Future University in Egypt | 36 | 2020-10-11 | 2022-09-08 |
| New Antiviral Drugs for Treatment of COVID-19 Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days : - COVID, Drug Effect | Phase 3 | Unknown | Mansoura University | 100 | 2020-10-01 | 2020-09-03 |
| IFN Beta-1b and Ribavirin for Covid-19 Interferon beta-1b, Ribavirin - Covid19 | Phase 2 | Unknown | The University of Hong Kong | 96 | 2020-07-29 | 2020-07-31 |
| Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: - Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension | Recruiting | Duke University | 5000 | 2020-03-05 | 2026-08-21 |
Showing 20 of 771. Sign in to see all of them.
Hepatitis C, Chronic (399) · Hepatitis C (388) · HIV Infections (46) · Hepatitis (29) · Fibrosis (25) · Liver Diseases (18) · Hepatitis, Chronic (13) · Acquired Immunodeficiency Syndrome (11) · Infections (11) · Liver Cirrhosis (10) · Insulin Resistance (9) · COVID-19 (8) · Recurrence (8) · Bronchiolitis Obliterans Syndrome (7) · Carcinoma, Hepatocellular (7)
Merck Sharp & Dohme LLC (97) · Hoffmann-La Roche (67) · Bristol-Myers Squibb (41) · AbbVie (35) · Gilead Sciences (33) · National Institute of Allergy and Infectious Diseases (NIAID) (23) · Vertex Pharmaceuticals Incorporated (19) · AbbVie (prior sponsor, Abbott) (15) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (12) · ANRS, Emerging Infectious Diseases (11) · Boehringer Ingelheim (11) · National Taiwan University Hospital (10) · Debiopharm International SA (9) · Janssen R&D Ireland (8) · Kaohsiung Medical University Chung-Ho Memorial Hospital (8)
United States (262) · France (105) · Germany (101) · Canada (84) · Spain (83) · Puerto Rico (82) · United Kingdom (67) · Australia (62) · Italy (60) · Belgium (42) · Poland (42) · Austria (40) · Taiwan (39) · Japan (31) · New Zealand (31)
Chen-Hua Liu, MD (7) · Robert H. Hyland, DPhil (5) · Daniel Cohen, MD (4) · Eric Cohen, MD (4)
PMID 29377566, PMID 25445400, PMID 30739368, PMID 23607594, PMID 26947564, PMID 28193518, PMID 29461687, PMID 16122679, PMID 19330875, PMID 20189674, PMID 22239511, PMID 22626609, PMID 23281974, PMID 24154738, PMID 24428467, PMID 24982088, PMID 25164700, PMID 25196718, PMID 26321288, PMID 26596948, PMID 26683763, PMID 26743093, PMID 26752189, PMID 26936417, PMID 27920566, PMID 28802814, PMID 28802816, PMID 29404492, PMID 30012435, PMID 30923816, PMID 30977945, PMID 31568620, PMID 35339025, PMID 10761562, PMID 10921388, PMID 10965678, PMID 11059069, PMID 11059125, PMID 11413125, PMID 11984144, PMID 12375147, PMID 12450640, PMID 12618532, PMID 12823087, PMID 15147119, PMID 15158348, PMID 15191208, PMID 15282352, PMID 15316341, PMID 15374882
2014 (15), 2009 (12), 2015 (9), 2008 (6), 2004 (5), 2005 (4), 2016 (2), UM1AI068636 (2), 2023 (1), K23DA022454 (1), K23DK082621 (1), R01AI049141 (1), R01AI049508 (1), R01DA016764 (1), R01DA026727 (1)